Literature DB >> 28968669

Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.

Robert W Shafer1.   

Abstract

As treatment options coalesce around a smaller number of antiretroviral drugs (ARVs), data are emerging on the drug resistance mutations (DRMs) selected by the most widely used ARVs and on the impact of these DRMs on ARV susceptibility and virological response to first- and later-line treatment regimens. Recent studies have described the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitors raltegravir and elvitegravir. Several small studies have described DRMs that emerge in patients receiving dolutegravir.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antiviral drug therapy; human immunodeficiency virus type 1; integrase; protease; reverse transcriptase

Mesh：

Substances：

Year:  2017        PMID： 28968669      PMCID： PMC5853262          DOI： 10.1093/infdis/jix398

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  56 in total

1.  Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Authors:  Tomokazu Yoshinaga; Masanori Kobayashi; Takahiro Seki; Shigeru Miki; Chiaki Wakasa-Morimoto; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark R Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

3.  HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.

Authors:  Jean d'Amour Ndahimana; David J Riedel; Ribakare Muhayimpundu; Sabin Nsanzimana; Gad Niyibizi; Emmanuel Mutaganzwa; Augustin Mulindabigwi; Cyprien Baribwira; Athanase Kiromera; Linda L Jagodzinski; Sheila A Peel; Robert R Redfield
Journal:  Antivir Ther       Date:  2015-11-12

4.  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Authors:  George L Melikian; Soo-Yon Rhee; Vici Varghese; Danielle Porter; Kirsten White; Jonathan Taylor; William Towner; Paolo Troia; Jeffrey Burack; Edwin Dejesus; Gregory K Robbins; Kristin Razzeca; Ron Kagan; Tommy F Liu; W Jeffrey Fessel; Dennis Israelski; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2013-08-09       Impact factor: 5.790

5.  Evolution of tenofovir-resistant HIV-1 isolates exposed to tenofovir alafenamide dose escalation.

Authors:  Stephanie Cox; Nicolas Margot; Renee Ram; Audun Johnson; Michael Miller; Christian Callebaut
Journal:  Antiviral Res       Date:  2017-03-28       Impact factor: 5.970

6.  Emergent drug resistance with integrase strand transfer inhibitor-based regimens.

Authors:  Katherine J Lepik; P Richard Harrigan; Benita Yip; Lu Wang; Marjorie A Robbins; Wendy W Zhang; Junine Toy; Linda Akagi; Viviane D Lima; Silvia Guillemi; Julio S G Montaner; Rolando Barrios
Journal:  AIDS       Date:  2017-06-19       Impact factor: 4.177

7.  The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

Authors:  Evguenia S Svarovskaia; Joy Y Feng; Nicolas A Margot; Florence Myrick; Derrick Goodman; John K Ly; Kirsten L White; Nilima Kutty; Ruth Wang; Katyna Borroto-Esoda; Michael D Miller
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

8.  Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.

Authors:  Bluma G Brenner; Réjean Thomas; José Luis Blanco; Ruxandra-Ilinca Ibanescu; Maureen Oliveira; Thibault Mesplède; Olga Golubkov; Michel Roger; Federico Garcia; Esteban Martinez; Mark A Wainberg
Journal:  J Antimicrob Chemother       Date:  2016-03-29       Impact factor: 5.790

9.  Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.

Authors:  Gaston R Picchio; Laurence T Rimsky; Veerle Van Eygen; Mojgan Haddad; Laura A Napolitano; Johan Vingerhoets
Journal:  Antivir Ther       Date:  2014-04-04

10.  Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Authors:  Kristof Theys; Kristel Van Laethem; Perpetua Gomes; Guy Baele; Andrea-Clemencia Pineda-Peña; Anne-Mieke Vandamme; Ricardo J Camacho; Ana B Abecasis
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205
View more
  9 in total

1.  Halogen Bond Interactions of Novel HIV-1 Protease Inhibitors (PI) (GRL-001-15 and GRL-003-15) with the Flap of Protease Are Critical for Their Potent Activity against Wild-Type HIV-1 and Multi-PI-Resistant Variants.

Authors:  Shin-Ichiro Hattori; Hironori Hayashi; Haydar Bulut; Kalapala Venkateswara Rao; Prasanth R Nyalapatla; Kazuya Hasegawa; Manabu Aoki; Arun K Ghosh; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Authors:  Rachel Van Duyne; Lillian S Kuo; Phuong Pham; Ken Fujii; Eric O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

3.  HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.

Authors:  Linah N Rusere; Gordon J Lockbaum; Sook-Kyung Lee; Mina Henes; Klajdi Kosovrasti; Ean Spielvogel; Ellen A Nalivaika; Ronald Swanstrom; Nese Kurt Yilmaz; Celia A Schiffer; Akbar Ali
Journal:  J Med Chem       Date:  2019-08-21       Impact factor: 7.446

4.  Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.

Authors:  Jennifer A Fulcher; Yushen Du; Tian-Hao Zhang; Ren Sun; Raphael J Landovitz
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

5.  Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.

Authors:  Koen K A Van Rompay; Said Hassounah; Brandon F Keele; Jeffrey D Lifson; Amir Ardeshir; Jennifer Watanabe; Hanh Thi Pham; Elena Chertova; Raymond Sowder; Jan Balzarini; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

6.  Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.

Authors:  Giselle de Faria Romero Soldi; Isadora Coutinho Ribeiro; Cintia Mayumi Ahagon; Luana Portes Ozório Coelho; Gabriela Bastos Cabral; Giselle Ibette Silva López Lopes; João Leandro de Paula Ferreira; Luís Fernando de Macedo Brígido
Journal:  PLoS One       Date:  2019-10-01       Impact factor: 3.240

7.  Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in Botswana.

Authors:  Dorcas Maruapula; Iain J MacLeod; Sikhulile Moyo; Rosemary Musonda; Kaelo Seatla; Kesaobaka Molebatsi; Melvin Leteane; Max Essex; Simani Gaseitsiwe; Christopher F Rowley
Journal:  AAS Open Res       Date:  2021-05-07

8.  Occurrence of the S230R integrase strand inhibitor mutation in a treatment-naïve individual case report.

Authors:  Smitha Gudipati; Indira Brar; Alicia Golembieski; Zachary Hanna; Norman Markowitz
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

9.  First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium.

Authors:  Géraldine Dessilly; Léonie Goeminne; Anne-Thérèse Vandenbroucke; François E Dufrasne; Anandi Martin; Benoît Kabamba-Mukadi
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.